Elanco Animal Health Incorporated (ELAN)
| Market Cap | 11.86B +29.5% |
| Revenue (ttm) | 5.02B +12.0% |
| Net Income | -199.00M |
| EPS | -0.41 |
| Shares Out | 499.62M |
| PE Ratio | n/a |
| Forward PE | 19.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,533,442 |
| Open | 23.91 |
| Previous Close | 23.97 |
| Day's Range | 23.67 - 23.96 |
| 52-Week Range | 18.22 - 27.98 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 31.21 (+31.47%) |
| Earnings Date | Aug 5, 2026 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ELAN stock is "Strong Buy." The 12-month stock price target is $31.21, which is an increase of 31.47% from the latest price.
News
Elanco announces completion of manufacturing expansion at Elwood
Elanco (ELAN) Animal Health announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with m...
Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ --...
Elanco CLiK Extra receives FDA Emergency Use Authorization
Elanco (ELAN) announced it has received Emergency Use Authorization from the U.S. Food and Drug Administration for CLiK Extra wound spray for application on or around wounds to prevent infestations…
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra pro...
Elanco CEO on Boosted Forecast, Surge in Tick Bites
Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent...
Elanco price target raised to $33 from $31 at UBS
UBS analyst Andrea Alfonso raised the firm’s price target on Elanco (ELAN) to $33 from $31 and keeps a Buy rating on the shares.
Elanco price target raised to $34 from $31 at Citi
Citi raised the firm’s price target on Elanco (ELAN) to $34 from $31 and keeps a Buy rating on the shares.
Elanco price target raised to $30 from $29 at KeyBanc
KeyBanc raised the firm’s price target on Elanco (ELAN) to $30 from $29 and keeps an Overweight rating on the shares. The firm notes the company posted a solid beat…
Elanco Animal Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 8% organic revenue growth, margin expansion, and strong innovation-driven gains, especially from Zenrelia and Credelio Quattro. Full-year guidance was raised for revenue, EBITDA, and EPS, with continued investment in launches and productivity initiatives.
Elanco Animal Health Earnings release: Q2 2026
Elanco Animal Health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Elanco Animal Health Slides: Q2 2026
Elanco Animal Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Elanco Animal Health Quarterly report: Q2 2026
Elanco Animal Health has published its Q2 2026 quarterly earnings report on August 5, 2026.
Elanco reports Q2 adjusted EPS 34c, consensus 27c
Reports Q2 revenue $1.37B, consensus $1.31B. “Elanco’s (ELAN) second quarter results demonstrate our momentum and leadership in the attractive animal health industry,” stated Jeff Simmons, President a...
Elanco Animal Health Reports Second Quarter 2026 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% or...
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /...
Elanco price target raised to $26 from $23 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Elanco (ELAN) to $26 from $23 and keeps an Equal Weight rating on the shares. U.S. vet practices are…
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours...
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct...
Elanco price target raised to $32 from $31 at TD Cowen
TD Cowen analyst Steve Scala raised the firm’s price target on Elanco (ELAN) to $32 from $31 and keeps a Buy rating on the shares. The firm said seven potential…
Elanco to launch Elanco Ventures for animal health innovation
Elanco (ELAN) Animal Health plans to establish Elanco Ventures, a dedicated corporate venture capital platform designed to support, invest and advance innovation in animal health. To be backed by a…
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: E...
Elanco announces USDA approval of TruCan Ultra Lyme-L4
Elanco (ELAN) Animal Health announced the U.S. Department of Agriculture approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vacc...
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine...
Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'
Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.
Confirmed screwworm case in Texas sends two biotech stocks higher
Options volume is surging for Zoetis as traders look for potential stock market winners in light of a screwworm case in Texas.